Gene expression profiling in frataxin deficient mice: Microarray evidence for significant expression changes without detectable neurodegeneration
被引:41
作者:
Coppola, G
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Coppola, G
Choi, SH
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Choi, SH
Santos, MM
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Santos, MM
Miranda, CJ
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Miranda, CJ
Tentler, D
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Tentler, D
Wexler, EM
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Wexler, EM
Pandolfo, M
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Pandolfo, M
Geschwind, DH
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
Geschwind, DH
[1
]
机构:
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, 710 Westwood Pl, Los Angeles, CA 90095 USA
[2] Korea Univ, Coll Med, Dept Pharmacol, Seoul 136705, South Korea
[3] CHUM Hop Notre Dame, Ctr Rech, Quebec City, PQ H2L 4M1, Canada
[4] Univ Libre Bruxelles, Hop Erasme, Serv Neurol, Brussels, Belgium
Friedreich's ataxia (FRDA) is caused by reduction of frataxin levels to 5-35%. To better understand the biochemical sequelae of frataxin reduction, in absence of the confounding effects of neurodegeneration, we studied the gene expression profile of a mouse model expressing 25-36% of the normal frataxin levels, and not showing a detectable phenotype or neurodegenerative features. Despite having no overt phenotype, a clear microarray gene expression phenotype was observed. This phenotype followed the known regional susceptibility in this disease, most changes occurring in the spinal cord. Additionally, gene ontology analysis identified a clear mitochondrial component, consistent with previous findings. We were able to confirm a subset of changes in fibroblast cell lines from patients. The identification of a core set of genes changing early in the FRDA pathogenesis can be a useful tool in both clarifying the disease process and in evaluating new therapeutic strategies. (c) 2006 Elsevier Inc. All rights reserved.